The Life Sciences team advised Rapport Therapeutics, Inc. on its launch with a $100 million Series A financing from Third Rock Ventures, ARCH Venture Partners and Johnson & Johnson Innovation – JJDC, Inc. (JJDC).
Rapport’s novel platform utilizes discoveries made by its scientific founders to identify receptor-associated proteins that enable the identification of precision targeted small molecule drugs that have the potential to transform the treatment of neurological disorders. The company’s lead program is currently in Phase 1 studies for the treatment of drug-resistant seizure disorders.
Rapport is a clinical-stage biotechnology company dedicated to the discovery and development of precision medicines for neurological disorders.
The Goodwin team was led by Stephanie Richards, Larissa Pinho, Frank Qin, Aniko Bouley, and Kingsley Taft.
For more details, read the press release and articles in BioSpace, Endpoints News, and Fierce Biotech.